These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 14745377)

  • 1. Conference report - antiretroviral therapy update from the 9th European AIDS Conference.
    Conway B
    MedGenMed; 2003 Dec; 5(4):30. PubMed ID: 14745377
    [No Abstract]   [Full Text] [Related]  

  • 2. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
    JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis.
    Moyle GJ; Gazzard BG
    AIDS; 2002 May; 16(7):1086-7. PubMed ID: 11953482
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-HIV agents. Abacavir--as good as AZT?
    TreatmentUpdate; 2003 Oct; 15(6):3-4. PubMed ID: 17216861
    [No Abstract]   [Full Text] [Related]  

  • 5. Triple nuke therapy--results after one year.
    TreatmentUpdate; 2001; 12(10):3-4. PubMed ID: 11570063
    [No Abstract]   [Full Text] [Related]  

  • 6. Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095.
    Feinberg J
    AIDS Clin Care; 2006 Nov; 18(11):99. PubMed ID: 17183745
    [No Abstract]   [Full Text] [Related]  

  • 7. [First HIV triple therapy with one tablet].
    Dtsch Med Wochenschr; 2000 Feb; 125(8):A22. PubMed ID: 10723466
    [No Abstract]   [Full Text] [Related]  

  • 8. AIDS drug in halted trial less effective as monotherapy.
    AIDS Read; 2003 Apr; 13(4):159. PubMed ID: 12741364
    [No Abstract]   [Full Text] [Related]  

  • 9. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
    Henry K; Wallace RJ; Bellman PC; Norris D; Fisher RL; Ross LL; Liao Q; Shaefer MS;
    J Infect Dis; 2001 Feb; 183(4):571-8. PubMed ID: 11170982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New formulations approved for children.
    AIDS Patient Care STDS; 2008 Jan; 22(1):88. PubMed ID: 18453043
    [No Abstract]   [Full Text] [Related]  

  • 11. AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial.
    Gallant JE
    Hopkins HIV Rep; 2003 Jul; 15(4):1-2. PubMed ID: 14696559
    [No Abstract]   [Full Text] [Related]  

  • 12. AIDS foundation seeks withdrawal of approval for HIV drug combination.
    Clarke B
    Lancet Infect Dis; 2003 Oct; 3(10):604. PubMed ID: 14558502
    [No Abstract]   [Full Text] [Related]  

  • 13. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.
    Green H; Gibb DM; Walker AS; Pillay D; Butler K; Candeias F; Castelli-Gattinara G; Compagnucci A; Della Negra M; de Rossi A; Feiterna-Sperling C; Giaquinto C; Harper L; Levy J; Saidi Y; Wintergerst U;
    AIDS; 2007 May; 21(8):947-55. PubMed ID: 17457088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Where now for Trizivir? Role of the triple-NRTI pill post-ACTG 5095.
    Moyle GJ
    AIDS Read; 2003 May; 13(5):223-4, 227, 244. PubMed ID: 12800825
    [No Abstract]   [Full Text] [Related]  

  • 15. Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results.
    Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Van Kasteren ME; Bravenboer B; Ten Kate RW; Groeneveld PH; van der Werf TS; Gisolf EH; Richter C
    AIDS Patient Care STDS; 2010 Jun; 24(6):361-6. PubMed ID: 20515418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
    Shey MS; Kongnyuy EJ; Alobwede SM; Wiysonge CS
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD005481. PubMed ID: 23543540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trizivir on the market.
    Kerr C
    Trends Microbiol; 2001 Jan; 9(1):13. PubMed ID: 11166234
    [No Abstract]   [Full Text] [Related]  

  • 18. [Efficacy and safety of the substitution of zidovudine by nevirapine in treatments based on three nucleoside analogue reverse transcriptase inhibitors in HIV-1 infected patients].
    Tasias M; Ruiz S; Deig E; Pedrol E
    Enferm Infecc Microbiol Clin; 2011; 29(7):556-7. PubMed ID: 21565428
    [No Abstract]   [Full Text] [Related]  

  • 19. Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.
    Stürmer M; Dauer B; Moesch M; Haberl A; Mueller A; Locher L; Knecht G; Hanke N; Doerr HW; Staszewski S
    Antivir Ther; 2007; 12(1):25-30. PubMed ID: 17503744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.
    Sáez-Llorens X; Nelson RP; Emmanuel P; Wiznia A; Mitchell C; Church JA; Sleasman J; Van Dyke R; Richardson CG; Cutrell A; Spreen W; Hetherington S
    Pediatrics; 2001 Jan; 107(1):E4. PubMed ID: 11134468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.